- Global Pharma News & Resources

Rerum Novarum Announces Dr. Rivka Riven Kreitman, to Join Scientific Board

Rerum Novarum Announces Dr. Rivka Riven Kreitman, to Join Scientific Board

PR Newswire

PHILADELPHIA, Dec. 4, 2018

PHILADELPHIA, Dec. 4, 2018 /PRNewswire/ -- Rerum Novarum, Inc., a Philadelphia-based firm dedicated to the support of university and corporate technology transfer and to the global commercialization of innovation, announces the appointment of Rivka Kreitman, Ph.D. to the Scientific Board.  Dr. Kreitman brings decades of scientific research, drug development and management experience to Rerum Novarum.

We are pleased to welcome Dr. Kreitman to the Rerum Novarum Scientific Board.  Dr. Kreitman is presently responsible for leading the Global Branded Regulatory Affairs department in Teva Pharmaceutical Industries, Ltd., assuring the smooth development and approval of all Teva's new products, and maintaining the ones that reached the market in compliance with global health authorities' regulations. Dr. Kreitman is a Global Pharmaceutical Executive, with over 35 years of broad academic and pharma experience and over 25 years of experience in diverse areas including business development, pharmacology, Clinical operations, managing the North America IR&D function, heading the Global Innovative Research and Development (IR&D) at Teva and Global strategic marketing.

"We are delighted to have Dr. Kreitman join the Rerum Novarum team.  Her credentials, her creativity, and her passion for her work will enhance our ability to continue moving forward by further building our scientific strategy, and by deepening our intellectual insight," stated Lawrence Agulnick, Rerum Novarum's Chief Executive Officer.  Mike Andrus, Rerum Novarum's SVP of Business Development notes, "Dr. Kreitman's extensive experience in CNS, Autoimmune diseases, and Oncology allows us to round out our scientific advisory team.  We believe that Dr. Kreitman will be instrumental in furthering our scientific and business efforts in supporting global tech transfer and the global commercialization of novel discoveries."

"I am pleased to join Rerum Novarum Scientific Board and focus my involvement on advancing the company's lead projects," stated Dr. Kreitman.  "Working in both scientific research and in Pharmaceutical business has given me tremendous insight into the opportunities and challenges of successful global commercialization.  I look forward to working with Rerum Novarum in its efforts to support and guide the global delivery of innovative solutions."

About Rerum Novarum

Rerum Novarum's mission is to identify and support the launch of significant technologies in the global marketplace. At our core, we are a team of business, science, technology, and entrepreneurial experts that harness a confluence of expertise, funding, and innovation to commercialize key technological advances in many industries across Europe, the United States, Africa, and Asia. For further information, please visit

Safe Harbor

Certain matters discussed in this release may constitute forward-looking statements for the purposes of the Federal Securities Laws, and as such, may involve known and unknown risk.  Uncertainties and other factors may cause actual results, performance or activities of Rerum Novarum, Inc. to be materially different from future results of performance or achievements expressed or implied by such forward-looking statements. 

Rerum Novarum Contact:
Lawrence Agulnick
Chief Executive Officer
Rerum Novarum, Inc.
1500 Market Street
12th Floor
Philadelphia, PA 19102
(610) 513-9446

Media Contact:
Malika Shettar
Rerum Novarum, Inc.
(601) 988-5502

View original content to download multimedia:

SOURCE Rerum Novarum, Inc.

Editor Details

Last Updated: 04-Dec-2018